Dutch biotech rais­es €30M for up­scaled man­u­fac­tur­ing, pi­lot study of blood clot­ting drug

Var­mX, a Dutch biotech de­vel­op­ing a re­ver­sal agent for blood thin­ners, has bagged a €30 mil­lion Se­ries B2 round as it gets ready to launch a piv­otal tri­al.

Spun out of the lab of founder Pieter Re­its­ma at Lei­den Uni­ver­si­ty Med­ical Cen­ter, the com­pa­ny’s lead com­pound, VMX-C001, is de­signed to re­verse the ef­fects of car­dio­vas­cu­lar drugs that pre­vent blood clots — so that pa­tients who are on those drugs can stop bleed­ing when they need to.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER